EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

(S)-(-)-blebbistatin O-benzoate has the potential to improve atopic dermatitis symptoms in NC/Nga mice by upregulating epidermal barrier function and inhibiting type 2 alarmin cytokine induction

Shunya Sahara iD, Ayumi Ueno, Natsuki Wakita, Miki Iwai, Junki Uda, Koich Nakaoji, Kazuhiko Hamada, Akito Maeda, Yasufumi Kaneda, Manabu Fujimoto

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0302781 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Shunya Sahara und 9 weiteren Autor:innen. Beteiligte Einrichtung: Research and Development Division, PIAS Corporation, Kobe, Hyogo, Japan. Hauptthemen laut MEDLINE: Benzoates, Cytokines, Dermatitis, Atopic, Epidermis. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atopic dermatitis is a multi-pathogenic disease characterized by chronic skin inflammation and barrier dysfunction. Therefore, improving the skin’s ability to form an epidermal barrier and suppressing the production of cytokines that induce type 2 inflammatory responses are important for controlling atopic dermatitis symptoms. (-)-Blebbistatin, a non-muscle myosin II inhibitor, has been suggested to improve pulmonary endothelial barrier function and control inflammation by suppressing immune cell migration; however, its efficacy in atopic dermatitis is unknown. In this study, we investigated whether (S)-(-)-blebbistatin O-benzoate, a derivative of (-)-blebbistatin, improves dermatitis symptoms in a mite antigen-induced atopic dermatitis model using NC/Nga mice. The efficacy of the compound was confirmed using dermatitis scores, ear thickness measurements, serum IgE levels, histological analysis of lesions, and filaggrin expression analysis, which is important for barrier function. (S)-(-)-Blebbistatin O-benzoate treatment significantly reduced the dermatitis score and serum IgE levels compared to those in the vehicle group ( p < 0.05). Furthermore, the histological analysis revealed enhanced filaggrin production and a decreased number of mast cells ( p < 0.05), indicating that (S)-(-)-blebbistatin O-benzoate improved atopic dermatitis symptoms in a pathological model. In vitro analysis using cultured keratinocytes revealed increased expression of filaggrin, loricrin, involucrin, and ceramide production pathway-related genes, suggesting that (S)-(-)-blebbistatin O-benzoate promotes epidermal barrier formation. Furthermore, the effect of (S)-(-)-blebbistatin O-benzoate on type 2 alarmin cytokines, which are secreted from epidermal cells upon scratching or allergen stimulation and are involved in the pathogenesis of atopic dermatitis, was evaluated using antigens derived from mite feces. The results showed that (S)-(-)-blebbistatin O-benzoate inhibited the upregulation of these cytokines. Based on the above, (S)-(-)-blebbistatin O-benzoate has the potential to be developed as an atopic dermatitis treatment option that controls dermatitis symptoms by suppressing inflammation and improving barrier function by acting on multiple aspects of the pathogenesis of atopic dermatitis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BenzoatesCytokinesDermatitis, AtopicEpidermisFilaggrin ProteinsHeterocyclic Compounds, 4 or More RingsAnimalsHumansMaleMiceAntigens, DermatophagoidesDisease Models, AnimalImmunoglobulin EIntermediate Filament ProteinsKeratinocytesAlarmins

Substanzen

Antigens, DermatophagoidesBenzoatesblebbistatinCytokinesFilaggrin ProteinsFLG protein, humanHeterocyclic Compounds, 4 or More RingsImmunoglobulin EIntermediate Filament ProteinsAlarmins

Autor:innen und Institutionen

  • Research and Development Division, PIAS Corporation, Kobe, Hyogo, Japan.
  • Office of Management and Planning, Osaka University, Suita, Osaka, Japan.
  • Vice President Office, Osaka University, Suita, Osaka, Japan.
  • Department of Dermatology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.

ORCID-Profile: Shunya Sahara

Zitieren

APA

Sahara, S., Ueno, A., Wakita, N., Iwai, M., Uda, J., Nakaoji, K., Hamada, K., Maeda, A., Kaneda, Y., & Fujimoto, M. (2024). (S)-(-)-blebbistatin O-benzoate has the potential to improve atopic dermatitis symptoms in NC/Nga mice by upregulating epidermal barrier function and inhibiting type 2 alarmin cytokine induction. PLOS ONE. https://doi.org/10.1371/journal.pone.0302781

Vancouver

Sahara S, Ueno A, Wakita N, Iwai M, Uda J, Nakaoji K, et al. (S)-(-)-blebbistatin O-benzoate has the potential to improve atopic dermatitis symptoms in NC/Nga mice by upregulating epidermal barrier function and inhibiting type 2 alarmin cytokine induction. PLOS ONE. 2024. doi:10.1371/journal.pone.0302781

BibTeX
@article{Sahara2024,
  author = {Sahara, Shunya and Ueno, Ayumi and Wakita, Natsuki and Iwai, Miki and Uda, Junki and Nakaoji, Koich and Hamada, Kazuhiko and Maeda, Akito and Kaneda, Yasufumi and Fujimoto, Manabu},
  title = {(S)-(-)-blebbistatin O-benzoate has the potential to improve atopic dermatitis symptoms in NC/Nga mice by upregulating epidermal barrier function and inhibiting type 2 alarmin cytokine induction},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0302781}
}
Kostenlos starten →